PLENARY KEYNOTE SESSIONS

Tuesday, August 8, 2023 | 11:05 – 11:40

Advances in Cellular Immunotherapies

Cokey Nguyen, PhD, CSO and CTO, Atara Biotherapeutics, Inc.
Allogeneic EBV T cell therapies: ushering in the next wave of innovation opportunities and challenges for different cell therapy platforms and approaches. Our journey behind the EU approval of the industry’s first-ever allogeneic T cell therapy and how this experience is aiding us to design the next generation of CAR T to overcome limitations of therapies today.

Tuesday, August 8, 2023 | 1:10 – 1:40 PM

The Outlook for Biotech Innovation in I-O and Cell Therapy

It has been a challenging year (or more) for the biotech market, with significant external pressures on the ‘classical’ I-O, bispecific immune cell engager and cell therapy spaces in particular. How have these external pressures manifested, and what strategic shifts have preclinical and clinical-stage companies in these spaces had to make? What are the implications for new company creation efforts, and what scientific advances are creating tailwinds despite the challenging market environment? This insider VC panel shares their perspectives.

Panel Moderator:

David R. Kaufman, MD, PhD, Partner, Third Rock Ventures LLC
It has been a challenging year (or more) for the biotech market, with significant external pressures on the ‘classical’ I-O, bispecific immune cell engager and cell therapy spaces in particular. How have these external pressures manifested, and what strategic shifts have preclinical and clinical-stage companies in these spaces had to make? What are the implications for new company creation efforts, and what scientific advances are creating tailwinds despite the challenging market environment? This insider VC panel shares their perspectives.